218 related articles for article (PubMed ID: 31918275)
1. Molecular mechanisms and clinical application of Iguratimod: A review.
Jiang H; Gao H; Wang Q; Wang M; Wu B
Biomed Pharmacother; 2020 Feb; 122():109704. PubMed ID: 31918275
[TBL] [Abstract][Full Text] [Related]
2. Iguratimod for the treatment of rheumatoid arthritis in Japan.
Tanaka K; Yamaguchi T; Hara M
Expert Rev Clin Immunol; 2015 May; 11(5):565-73. PubMed ID: 25797025
[TBL] [Abstract][Full Text] [Related]
3. Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.
Xiao W; Guo JP; Li C; Ye H; Wei W; Zou Y; Dai L; Li Z; Zhang M; Li X; Cai X; Zhao J; Wang Y; Tao Y; Liu D; Li Y; Wu M; Sun E; Wu L; Luo L; Mu R; Li Z
Pharmacogenomics; 2018 Apr; 19(5):383-392. PubMed ID: 29517409
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of iguratimod
Nozaki Y; Inoue A; Kinoshita K; Funauchi M; Matsumura I
Mod Rheumatol; 2020 Mar; 30(2):249-258. PubMed ID: 30676812
[No Abstract] [Full Text] [Related]
5. The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis.
Suto T; Yonemoto Y; Okamura K; Sakane H; Takeuchi K; Tamura Y; Kaneko T; Ayabe K; Chikuda H
Mod Rheumatol; 2019 Sep; 29(5):775-781. PubMed ID: 30092680
[No Abstract] [Full Text] [Related]
6. Iguratimod: a new disease-modifying antirheumatic drug.
Mucke HA
Drugs Today (Barc); 2012 Sep; 48(9):577-86. PubMed ID: 23032798
[TBL] [Abstract][Full Text] [Related]
7. Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients.
Ishikawa K; Ishikawa J
Mod Rheumatol; 2019 May; 29(3):418-429. PubMed ID: 29798702
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs.
Hu CJ; Zhang L; Zhou S; Jiang N; Zhao JL; Wang Q; Tian XP; Zeng XF
J Orthop Surg Res; 2021 Jul; 16(1):457. PubMed ID: 34271950
[TBL] [Abstract][Full Text] [Related]
9. Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases.
Long Z; Zeng L; He Q; Yang K; Xiang W; Ren X; Deng Y; Chen H
Front Immunol; 2023; 14():1150661. PubMed ID: 37809072
[TBL] [Abstract][Full Text] [Related]
10. [DMARDs (Focusing on iguratimod)].
Ito S
Nihon Rinsho; 2016 Jun; 74(6):948-54. PubMed ID: 27311184
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis.
Okamura K; Yonemoto Y; Okura C; Kobayashi T; Takagishi K
Mod Rheumatol; 2015 Mar; 25(2):235-40. PubMed ID: 25065917
[TBL] [Abstract][Full Text] [Related]
12. Anti-allodynic action of the disease-modifying anti-rheumatic drug iguratimod in a rat model of neuropathic pain.
Morimoto K; Miura A; Tanaka K
Inflamm Res; 2017 Oct; 66(10):855-862. PubMed ID: 28612120
[TBL] [Abstract][Full Text] [Related]
13. Iguratimod attenuates general disease activity and improves lung function in rheumatoid arthritis-associated interstitial lung disease patients.
Shu P; Shao SQ; Cai XN; Zhou DM; Ma H; Lu L; Yin HQ; Yin SL
Eur Rev Med Pharmacol Sci; 2021 Jul; 25(14):4687-4692. PubMed ID: 34337716
[TBL] [Abstract][Full Text] [Related]
14. The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
Ebina K; Miyama A; Tsuboi H; Kaneshiro S; Nishikawa M; Owaki H; Tsuji S; Hirao M; Etani Y; Goshima A; Hashimoto J; Yoshikawa H
Mod Rheumatol; 2019 Jul; 29(4):581-588. PubMed ID: 29882440
[No Abstract] [Full Text] [Related]
15. Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape.
Xie S; Li S; Tian J; Li F
Front Pharmacol; 2020; 11():73. PubMed ID: 32174824
[TBL] [Abstract][Full Text] [Related]
16. Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.
Yoshikawa A; Yoshida S; Kimura Y; Tokai N; Fujiki Y; Kotani T; Matsumura Y; Takeuchi T; Makino S
Mod Rheumatol; 2018 Mar; 28(2):227-234. PubMed ID: 28644744
[TBL] [Abstract][Full Text] [Related]
17. Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis.
Mizutani S; Kodera H; Sato Y; Nanki T; Yoshida S; Yasuoka H
Clin Rheumatol; 2021 Jan; 40(1):123-132. PubMed ID: 32506311
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis.
Liu S; Cui Y; Zhang X
Clin Rheumatol; 2021 Jan; 40(1):25-32. PubMed ID: 32506313
[TBL] [Abstract][Full Text] [Related]
19. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.
Luo Q; Sun Y; Liu W; Qian C; Jin B; Tao F; Gu Y; Wu X; Shen Y; Xu Q
J Immunol; 2013 Nov; 191(10):4969-78. PubMed ID: 24123677
[TBL] [Abstract][Full Text] [Related]
20. Iguratimod treatment reduces disease activity in early primary Sjögren's syndrome: An open-label pilot study.
Chen H; Qi X; Li Y; Wu Q; Shi Q; Wang L; Li J; Zhao L; Zhang L; Zhou X; Fei Y; Liu J; Su J; Wu D; Yang Y; Jiang H; Zeng X; Zhang F; Zhao Y
Mod Rheumatol; 2021 Mar; 31(2):394-398. PubMed ID: 32613869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
